Chaudhary, Varun http://orcid.org/0000-0002-9988-4146
Sarohia, Gurkaran S.
Phillips, Mark R. http://orcid.org/0000-0003-0923-261X
Park, Daniel
Xie, Jim
Zeraatkar, Dena
Fung, Matthew
Thabane, Lehana
Loewenstein, Anat http://orcid.org/0000-0002-7706-1165
Holz, Frank G. http://orcid.org/0000-0001-8019-9272
Garg, Sunir J.
Kaiser, Peter K.
Bhandari, Mohit
Guymer, Robyn H. http://orcid.org/0000-0002-9441-4356
Fraser-Bell, Samantha
Sivaprasad, Sobha
Wykoff, Charles C.
Article History
Received: 20 March 2022
Revised: 23 August 2022
Accepted: 16 September 2022
First Online: 11 November 2022
Competing interests
: VC: Advisory board: Alcon, Roche, Bayer, Novartis; Grants: Bayer, Novartis. GSS: Nothing to disclose. MRP: Nothing to disclose. DP: Nothing to disclose. JX: Nothing to disclose. DZ: Nothing to disclose. MF: Nothing to disclose. LT: Nothing to disclose. AL: Consultant: Allergan, Bayer, BeyeOnics, ForSight Labs, NotalVision, Novartis, Roche. FGH: Research funds: Acucela, Allergan, Apellis, Bayer, Bioeq/Formycon, Roche/Genentech, Geuder, Heidelberg Engineering, IvericBio, Kanghong, Novartis, NightStarX, Zeiss; Personal fees: Boehringer-Ingelheim, Grayburg Vision, LinBioscience, Pixium Vision, Stealth BioTherapeutics, Aerie, Oxurion. SJG: Consultant: Allergan, Apellis, Bausch and Lomb, Boehringer Ingelheim, Johnson and Johnson, Kanaph; Research funds: American Academy of Ophthalmology, Apellis, Boehringer Ingelheim, NGM Bio, Regeneron. RHG: Advisory boards: Bayer, Novartis, Apellis, Roche, Genentech Inc. PKK: Consultant: Novartis, Bayer, Biogen, Regeneron, Kanghong, Allergan, RegenxBio. MB: Research funds: Pendopharm, Bioventus, Acumed. SF-B: Consultant: Allergan, Bayer, Novartis. SS: Research funds: Novartis, Bayer, Allergan, Roche, Boehringer, Ingelheim and Optos Plc; Travel grants: Novartis, Bayer; Speaker fees: Novartis, Bayer and Optos Plc.; Advisory board: Novartis, Bayer, Allergan, Roche, Boehringer, Ingelheim, Optos Plz, Oxurion, Ophthea, Apellis, Oculis, Heidelberg Engineering. CCW: Consultant: Acuela, Adverum Biotechnologies, Inc, Aerpio, Alimera Sciences, Allegro Ophthalmics, LLC, Allergan, Apellis Pharmaceuticals, Bayer AG, Chengdu Kanghong Pharmaceuticals Group Co, Ltd, Clearside Biomedical, DORC (Dutch Ophthalmic Research Centre), EyePoint Pharmaceuticals, Gentech/Roche, GyroscopeTx, IVERIC bio, Kodiak Sciences Inc, Novartis AG, ONL Therapeutics, Oxurion NV, PolyPhotonix, Recens Medical, Regeron Pharmaceuticals, Inc, REGENXBIO Inc, Santen Pharmaceutical Co, Ltd, and Takeda Pharmaceutical Company Limited; Research funds: Adverum Biotechnologies, Inc, Aerie Pharmaceuticals, Inc, Aerpio, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Clearside Biomedical, Gemini Therapeutics, Genentech/Roche, Graybug Vision, Inc, GyroscopeTx, Ionis Pharmaceuticals, IVERIC bio, Kodiak Sciences Inc, Neurotech LLC, Novartis AG, Opthea, Outlook Therapeutics, Inc, Recens Medical, Regeneron Pharmaceuticals, Inc, REGENXBIO Inc, Samsung Pharm Co, Ltd, Santen Pharmaceutical Co, Ltd, Xbrane Biopharma AB. No other acknowledgements to list.